KAT7 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, designed to disrupt the KAT7 gene encoding the histone acetyltransferase HBO1. This polyclonal pool provides a heterogeneous loss-of-function model, avoiding clonal selection artifacts and enabling robust functional studies.
The parental A2780 line is an epithelial ovarian carcinoma model established from an untreated patient, widely utilized for investigating ovarian cancer biology, drug responses, and oncogenic signaling. Its adherent morphology, rapid proliferation, and well-characterized genetic background support reproducible experiments in cell cycle regulation, apoptosis, and epigenetic reprogramming.
KAT7 (HBO1) is a MYST family histone acetyltransferase that catalyzes histone H4 acetylation at lysines 5, 8, and 12 (H4K5ac, H4K8ac, H4K12ac), a modification critical for chromatin decondensation. As the catalytic subunit of the HBO1 acetyltransferase complex, it associates with scaffold proteins JADE1/2/3, ING4/5, BRPF1/2/3, and EAF6. Its expression is driven by the E2F1 transcription factor and c-MYC, while its activity is enhanced through cyclin A/CDK2-mediated phosphorylation. Acetylated H4 facilitates the loading of the MCM2-7 helicase complex onto replication origins by interacting with MCM2, ORC1, and CDT1, thereby licensing DNA replication and enabling S-phase entry. Beyond replication, KAT7 functions as a transcriptional coactivator, regulating gene networks involved in proliferation and cell cycle progression downstream of oncogenic pathways.
In the A2780 ovarian cancer context, KAT7 knockout impairs origin licensing, leading to delayed S-phase entry and reduced DNA replication. This disruption alters transcriptional programs governed by MYC and E2F1, ultimately inhibiting cell growth. The model is particularly suited for examining how histone acetylation dynamics influence replication stress responses, and for evaluating the therapeutic potential of targeting HBO1 in ovarian carcinoma. Crosstalk with Notch and MYC pathways can be explored, making these cells a valuable tool for epigenetic and cancer biology research.
These polyclonal knockout cells are designed for diverse assays: western blotting to detect changes in H4K5ac, H4K8ac, and H4K12ac; ChIP-qPCR to quantify histone acetylation at replication origins; co-immunoprecipitation to assess MCM2 interaction; flow cytometry with BrdU/PI staining for cell cycle analysis; and colony formation or MTT assays to measure proliferation. Additional applications include RNA-seq for transcriptome-wide profiling, RT-qPCR for target gene validation, and drug sensitivity testing. For further details, contact Ascent Research.
